| Name | Title | Contact Details |
|---|---|---|
Michelle Gomberg |
Associate Director Marketing Communications | Profile |
Susan Daniels |
Vice President R&D | Profile |
Reza Anayat |
VP & Head of Customer Success | Profile |
Wendy Chang |
Vice President, Head of People | Profile |
Wendy Chang |
Vice President and Head of People | Profile |
Predictive Biosciences is an innovative developer of molecular diagnostic tests for cancer diagnosis and monitoring. We are focused on understanding and meeting the needs of physicians by providing valuable diagnostic services and laboratory solutions.
The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.
Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.
RxGen is a Hamden, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The CereVasc eShunt™ device is intended to improve patient outcomes and redefine the treatment of communicating hydrocephalus.